What happened with CGEN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Compugen is a clinical-stage drug developer focused on cancer immunotherapy antibodies. Its Unigen computational platform uses artificial intelligence and biological data to identify potential drug targets, which it validates and uses to develop antibody candidates. It has no products approved for sale, so revenue comes from pharmaceutical partnerships rather than medicine sales.
Its active partners are AstraZeneca and Gilead. AstraZeneca develops rilvegostomig, which incorporates a component derived from Compugen’s COM902 antibody. Gilead licenses GS-0321, formerly COM503; Compugen conducts and pays for its Phase 1 trial before transferring development to Gilead. These arrangements bring Compugen upfront and milestone payments, with potential royalties if licensed products reach the market. Compugen also develops its own COM701 program for potential partnering.
The business depends heavily on these partners continuing development and on candidates succeeding in trials and gaining regulatory approval. Both partners can terminate their agreements. Israeli research-grant rules also restrict certain funded technology: transferring that know-how requires prior approval, and products incorporating it generally must be manufactured in Israel.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Compugen’s licensing income depends on AstraZeneca advancing rilvegostomig, a cancer antibody built using Compugen’s TIGIT antibodies, and paying upfront fees, milestones and royalties. Watch the first acceptance of its marketing application, which triggers the next milestone payment; Compugen retained most of its royalties on future sales.
Compugen depends on Gilead for milestone and royalty payments from its licensed GS-0321 cancer-antibody program, and for supplies of zimberelimab in the Phase 1 trial that Compugen runs and funds. Watch GS-0321’s trial progress and the transfer to Gilead, which then takes sole responsibility for development and commercialization.
Arcus Biosciences’ TIGIT cancer-trial failures have already weakened Compugen’s prospects for developing COM902 and finding a partner. After Arcus and Gilead stopped the Phase 3 STAR-221 study for futility, Compugen said it would not start new COM902 trials, though further TIGIT data could prompt it to reconsider.
BioNTech competes with Compugen’s COM701 through PM-1009, a cancer-antibody candidate acquired with Biotheus that targets the same immune checkpoint, PVRIG. Its trial progress matters because competing programs can draw eligible patients away and raise the efficacy bar for COM701.
Genmab’s Rina-S ovarian-cancer trial competes for patients with Compugen’s COM701 maintenance trial in relapsed platinum-sensitive ovarian cancer. Watch RAINFOL-04, which tests Rina-S plus standard care: its results could raise the efficacy bar that COM701 must meet.
Merck competes with Compugen for ovarian-cancer trial patients, and both develop TIGIT cancer therapies facing competing programs. Merck’s sacituzumab tirumotecan maintenance trial, with or without bevacizumab, overlaps with COM701’s patient population, making its enrollment and results relevant to Compugen’s trial prospects.
AbbVie’s mirvetuximab ovarian-cancer program competes with Compugen’s COM701 maintenance program for patients and potential treatment use. Watch the Phase 3 GLORIOSA trial of mirvetuximab plus bevacizumab, whose overlapping patient population puts pressure on COM701 enrollment and whose results could raise the treatment bar.
Agenus and Compugen compete to get their cancer checkpoint antibodies, including TIGIT programs, adopted in treatment and partnered with drug companies. Watch Agenus’s partnership efforts after it prioritized botensilimab and balstilimab and temporarily paused some non-core research and clinical work.
Arcus Biosciences, Inc. earningsRCUS
Arcus Biosciences’ TIGIT trial update will show whether this treatment approach has enough promise for Compugen to reconsider developing or partnering COM902.
Look for new TIGIT trial progress and results, especially evidence after STAR-221 stopped for futility. Findings that support further development could lead Compugen to revisit COM902 trials or a partnership; further disappointment would leave the program with less near-term potential for collaboration revenue or clinical progress.
Compugen Ltd earningsThis company
Compugen has no approved products and relies on collaboration payments and cash on hand to fund cancer-drug research; its report will show how research and trial costs affect its cash runway.
Read operating cash flow alongside cash, short-term deposits and marketable securities. Positive cash flow with enough reserves for planned trials would show Compugen can keep advancing programs on hand; negative cash flow or faster reserve depletion would mean development could bring funding pressure sooner, despite the current plan to fund operations into 2029.
